ARTICLE | Clinical News

AVI-7537 regulatory update

September 29, 2014 7:00 AM UTC

EMA's CHMP began a formal review of the available scientific information on Ebola treatments under development. The agency said its goal is to provide an overview of the current state of knowledge about therapies under development to support decision-making by health authorities. EMA said it has identified the following therapies: BCX4430 from BioCryst; hyperimmune horse sera from Fab'entech; ZMapp from Mapp; AVI-7537 from Sarepta; favipiravir from Fujifilm and MediVector; and TKM-Ebola from Tekmira. EMA said preventive vaccines and blood therapies involving the blood of survivors of Ebola are excluded from this review...